chylomicronemia

chylomicronemia

 [ki″lo-mi″kro-ne´me-ah]
an excess of chylomicrons in the blood.

chy·lo·mi·cro·ne·mi·a

(kī'lō-mī'krō-nē'mē-ă),
The presence of chylomicrons, especially increased numbers in the circulating blood, as in type I familial hyperlipoproteinemia.
See also: familial chylomicronemia syndrome.

chylomicronemia

/chy·lo·mi·cro·ne·mia/ (-mi″kron-e´me-ah) an excess of chylomicrons in the blood.

chy·lo·mi·cro·ne·mi·a

(kī'lō-mī-krō-nē'mē-ă)
The presence of chylomicrons, especially an increased number, in the circulating blood, as in type I familial hyperlipoproteinemia.
Synonym(s): chylomicronaemia.

chylomicronemia

an excess of chylomicrons in the blood.
References in periodicals archive ?
Food and Drug Administration (FDA) for volanesorsen, an investigational medicine for the treatment of familial chylomicronemia syndrome (FCS).
The most advanced drug in its pipeline, volanesorsen, has successfully completed a Phase 3 clinical program for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy, or FPL.
An absence of GPIHBP1 abolishes the entry of LPL into capillaries, causing severe chylomicronemia and an accumulation of catalytically active LPL in the interstitial spaces (Voss et al.
2 mmol/L Apolipoprotein A1 <10 mg/dL Refer patient to a lipid clinic or to a physician with special interest in lipids for further assessment of the following conditions Triglycerides Chylomicronemia syndrome with high risk of acute pancreatitis (24) LDL cholesterol Homozygous familial hypercholesterolemia with extremely high cardiovascular risk (44) LDL cholesterol Heterozygous familial hypercholesterolemia with high cardiovascular risk (43) LDL cholesterol in Heterozygous familial children hypercholesterolemia with high cardiovascular risk (45) Lp(a) Very high cardiovascular risk, i.
For this group, the term chylomicronemia syndrome is used, which is a result of interaction of genetic and secondary forms of hyperlipidemia.
The product is intended for the treatment of patients with Familial Chylomicronemia Syndrome.
Very severe triglyceride elevations (greater than 2,000 mg/dL) increase the risk of pancreatitis in the chylomicronemia syndrome.
Therapeutic plasma exchange in patients with chylomicronemia syndrome complicated by acute pancreatitis.
This was confirmed when the lipoprotein electrophoresis showed decreased alpha, increased prebeta, and normal beta fractions and chylomicronemia.
A mutation in the lipoprotein lipase gene is the molecular basis of Chylomicronemia in a colony of domestic cats.
Lomitapide is being evaluated for its ability to reduce LDL-C levels in patients with HoFH and reduce triglyceride levels in patients with familial chylomicronemia, or FC.
i) Familial Chylomicronemia Syndrome with either Lipoprotein Lipase (LPL) Deficiency or Apolipoprotein C II deficiency or